UNSPSC 51182215: Atosiban acetate

This classification denotes the acetate form of a hormone antagonist with the molecular formula C43H67N11O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 081D12SI0Z, chemically known as oxytocin, 1-(3-mercaptopropanoic acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine- but generally known as atosiban, which bears US NIH Compound Identifier 68613. European Medicines Agency schedules Atosiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05601MIG.

UNSPSC 51182215 Atosiban acetate, a Commodity code, represents pharmaceutical products procured through multistate cooperative purchasing vehicles for distribution across state and local government healthcare facilities. Atosiban acetate—a medication used in obstetric settings—is typically sourced as a generic multi-source pharmaceutical through standing supply agreements that serve hospitals, clinics, and other government-operated medical facilities across participating jurisdictions. The work involves establishing manufacturer-to-wholesaler supply chains with fixed or competitive pricing structures, compliance with cGMP and Drug Supply Chain Security Act requirements, and inventory management tied to specific NDC codes and packaging configurations. Issuing bodies procuring under this code are primarily multistate cooperative purchasing alliances administering contracts on behalf of multiple state agencies, counties, and municipalities rather than individual jurisdictions soliciting directly.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities including Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation weighs price competitiveness (75 percent), fixed pricing (10 percent), EDI capability (5 percent), compliance with administrative requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, carry commercial general liability insurance of $5,000,000 per occurrence, and agree to a two-year contract term with optional extensions at MMCAP's discretion.